Literature DB >> 28725964

Toward early detection of Helicobacter pylori-associated gastric cancer.

Rachel Walker1, Jan Poleszczuk2, Jaime Mejia3, Jae K Lee4, Jose M Pimiento5, Mokenge Malafa5, Anna R Giuliano6, Heiko Enderling1,7, Domenico Coppola8,9.   

Abstract

BACKGROUND: Gastric cancer is typically diagnosed at a late stage, leading to poor prognoses. Helicobacter pylori is responsible for 70% of gastric cancers globally, and patients with this bacterial infection often present with early stages of the carcinogenic pathway such as inflammation or gastritis. Although many patients continue to progress to advanced-stage disease after antibacterial treatment, there are no follow-up screening protocols for patients with a history of H. pylori.
METHODS: Several biomarkers (Lgr5, CD133, CD44) become upregulated during gastric carcinogenesis. A logistic regression model is developed using clinical data from 59 patients at different stages of the carcinogenic pathway to identify the likelihood of being at an advanced stage of disease for all combinations of age, sex, and marker positivity. Using these likelihood distributions and the observed rate of marker positivity increase, time to high likelihood (probability >0.8) of advanced disease for individual patients is predicted.
RESULTS: A strong correlation between marker positivity and disease stage was found for all three markers. Disease stage was accurately classified by the respective regression models for more than 86% of retrospective patients. Highly patient-specific predictions of time to onset of dysplasia were made, allowing the classification of 17 patients initially diagnosed with intestinal metaplasia into high-, intermediate-, or low-risk categories.
CONCLUSIONS: We present an approach designed to integrate pathology, mathematics, and statistics for detection of the earliest precancerous, treatable lesion. Given the simplicity and robustness of the framework, such technique has the potential to guide personalized screening schedules to minimize the risk of undetected malignant transformation.

Entities:  

Keywords:  Early detection of cancer; Helicobacter pylori; Stomach neoplasms

Mesh:

Substances:

Year:  2017        PMID: 28725964     DOI: 10.1007/s10120-017-0748-z

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  11 in total

1.  Helicobacter pylori and gastric cancer: both primary and secondary preventive measures are required.

Authors:  M Rugge; M Cassaro; G Leo; F Farinati; D Y Graham
Journal:  Arch Intern Med       Date:  1999-11-08

Review 2.  Prevention of gastric cancer by Helicobacter pylori eradication.

Authors:  Masahiro Asaka; Mototsugu Kato; David Y Graham
Journal:  Intern Med       Date:  2010-04-01       Impact factor: 1.271

3.  The time to eradicate gastric cancer is now.

Authors:  D Y Graham; A Shiotani
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

4.  CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion.

Authors:  Sang Hyuk Cho; Yeon Sun Park; Hun Jin Kim; Chang Hyun Kim; Sang Woo Lim; Jung Wook Huh; Jae Hyuk Lee; Hyeong Rok Kim
Journal:  Int J Oncol       Date:  2012-04-30       Impact factor: 5.650

5.  A model for gastric cancer epidemiology.

Authors:  P Correa; W Haenszel; C Cuello; S Tannenbaum; M Archer
Journal:  Lancet       Date:  1975-07-12       Impact factor: 79.321

Review 6.  Gastric cancer: diagnosis and treatment options.

Authors:  John C Layke; Peter P Lopez
Journal:  Am Fam Physician       Date:  2004-03-01       Impact factor: 3.292

7.  Intestinal stem cell marker LGR5 expression during gastric carcinogenesis.

Authors:  Zhi-Xue Zheng; Yu Sun; Zhao-De Bu; Lian-Hai Zhang; Zi-Yu Li; Ai-Wen Wu; Xiao-Jiang Wu; Xiao-Hong Wang; Xiao-Jing Cheng; Xiao-Fang Xing; Hong Du; Jia-Fu Ji
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

8.  Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma.

Authors:  Anahita Nosrati; Farshad Naghshvar; Somaieh Khanari
Journal:  Int J Mol Cell Med       Date:  2014

Review 9.  CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.

Authors:  Li Yiming; Guo Yunshan; Ma Bo; Zang Yu; Wei Tao; Liang Gengfang; Fan Dexian; Cui Shiqian; Jiang Jianli; Tang Juan; Chen Zhinan
Journal:  Oncotarget       Date:  2015-12-08

10.  Leucine-rich repeat-containing G-protein-coupled receptor 5 is associated with invasion, metastasis, and could be a potential therapeutic target in human gastric cancer.

Authors:  H Q Xi; A Z Cai; X S Wu; J X Cui; W S Shen; S B Bian; N Wang; J Y Li; C R Lu; Z Song; B Wei; L Chen
Journal:  Br J Cancer       Date:  2014-03-04       Impact factor: 7.640

View more
  3 in total

1.  CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression.

Authors:  Rachel Howard; Sameer Al Diffalha; Jose Pimiento; Jaime Mejia; Heiko Enderling; Anna Giuliano; Domenico Coppola
Journal:  Anticancer Res       Date:  2018-08       Impact factor: 2.480

2.  Immunohistochemical Analysis of LGR5 and TROY Expression in Gastric Carcinogenesis Demonstrates an Inverse Trend

Authors:  Samaneh Saberi; Abbas Piryaei; Esmat Mirabzadeh; Maryam Esmaeili; Toktam Karimi; Sara Momtaz; Afshin Abdirad; Niloofar Sodeifi; Mohammad Ali Mohagheghi; Hossein Baharvand; Marjan Mohammadi
Journal:  Iran Biomed J       Date:  2018-12-03

3.  Serum miR-101-3p combined with pepsinogen contributes to the early diagnosis of gastric cancer.

Authors:  Weiwei Zeng; Shuxiang Zhang; Lei Yang; Wenchao Wei; Jie Gao; Ni Guo; Fengting Wu
Journal:  BMC Med Genet       Date:  2020-02-10       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.